Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
|ClinicalTrials.gov Identifier: NCT00005027|
Recruitment Status : Completed
First Posted : August 8, 2003
Last Update Posted : April 5, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Drug: becatecarin||Phase 2|
- Determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue.
- Assess the quantitative and qualitative toxicities associated with this drug in this patient population.
OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer|
|Study Start Date :||June 2000|
|Actual Primary Completion Date :||March 2005|
|Actual Study Completion Date :||March 2005|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005027
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Study Chair:||Ulka N. Vaishampayan, MD||Barbara Ann Karmanos Cancer Institute|